Carl W White Selected Research

AEOL 10150

12/2016	From the Cover: Catalytic Antioxidant Rescue of Inhaled Sulfur Mustard Toxicity.
7/2014	Catalytic antioxidant AEOL 10150 treatment ameliorates sulfur mustard analog 2-chloroethyl ethyl sulfide-associated cutaneous toxic effects.
3/2011	AEOL10150: a novel therapeutic for rescue treatment after toxic gas lung injury.
5/2010	Treatment with the catalytic metalloporphyrin AEOL 10150 reduces inflammation and oxidative stress due to inhalation of the sulfur mustard analog 2-chloroethyl ethyl sulfide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl W White Research Topics

Disease

20	Hypoxia (Hypoxemia) 01/2022 - 09/2002
13	Inflammation (Inflammations) 10/2020 - 05/2007
11	Wounds and Injuries (Trauma) 05/2015 - 04/2011
9	Respiratory Insufficiency (Respiratory Failure) 01/2022 - 04/2004
8	Hyperoxia 01/2022 - 09/2002
8	Airway Obstruction (Choking) 11/2020 - 12/2010
6	Cystic Fibrosis (Mucoviscidosis) 02/2012 - 05/2004
5	Acute Lung Injury 01/2022 - 01/2012
5	Lung Injury 06/2017 - 04/2006
4	Asthma (Bronchial Asthma) 01/2020 - 07/2010
3	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 12/2013 - 11/2010
3	Bronchopulmonary Dysplasia 06/2007 - 02/2004
2	Poisoning 05/2022 - 01/2021
2	Pulmonary Hypertension 10/2020 - 07/2013
2	Airway Remodeling 01/2020 - 01/2017
2	Bronchiolitis Obliterans 01/2018 - 01/2017
2	Ataxia (Dyssynergia) 01/2018 - 06/2010
2	Bronchitis 02/2015 - 04/2013
2	Edema (Dropsy) 03/2014 - 03/2009
2	Vascular Remodeling 07/2013 - 12/2005
2	Respiratory Hypersensitivity 03/2011 - 10/2010
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2011 - 03/2009
2	Lung Diseases (Lung Disease) 01/2011 - 02/2004
2	Necrosis 06/2010 - 07/2002
2	Premature Birth (Birth, Premature) 06/2007 - 12/2005
1	Neoplasms (Cancer) 01/2022
1	Acidosis 11/2020
1	Hypertrophy 10/2020
1	Chorioamnionitis 10/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Hemangioma (Angioma) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2019
1	Lower Urinary Tract Symptoms 01/2019
1	Hypercapnia 01/2018
1	Fibrosis (Cirrhosis) 01/2018
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018
1	Respiratory Acidosis 01/2018
1	Seizures (Absence Seizure) 01/2018
1	Muscle Hypotonia (Hypotonia) 01/2018
1	Thrombosis (Thrombus) 10/2017

Drug/Important Bio-Agent (IBA)

22	Mustard Gas (Sulfur Mustard)IBA 01/2018 - 05/2010
14	2-chloroethyl ethyl sulfideIBA 02/2015 - 03/2009
9	Oxygen (Dioxygen)IBA 01/2022 - 02/2003
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2004
8	AntioxidantsIBA 12/2016 - 02/2004
6	FibrinIBA 11/2020 - 04/2013
6	Irritants (Vesicants)IBA 02/2015 - 07/2010
4	ThioredoxinsIBA 01/2022 - 05/2004
4	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2020 - 04/2013
4	OzoneIBA 01/2020 - 07/2010
4	ChlorineIBA 01/2018 - 07/2010
4	Biomarkers (Surrogate Marker)IBA 12/2016 - 10/2010
4	AEOL 10150IBA 12/2016 - 05/2010
4	Mechlorethamine (Nitrogen Mustard)FDA Link 05/2015 - 01/2013
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2007 - 04/2005
4	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 06/2007 - 04/2005
3	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2019 - 04/2012
3	Chemical Warfare AgentsIBA 01/2017 - 01/2012
3	Oxidants (Oxidizing Agents)IBA 06/2014 - 02/2004
3	Transcription Factors (Transcription Factor)IBA 07/2013 - 11/2002
3	CalciumIBA 01/2011 - 06/2007
3	Adenosine Triphosphate (ATP)IBA 12/2005 - 11/2002
2	cobinamideIBA 05/2022 - 01/2021
2	Sulfhydryl Compounds (Thiols)IBA 01/2022 - 01/2021
2	AntidotesIBA 01/2021 - 05/2015
2	Biological ProductsIBA 01/2020 - 06/2010
2	CollagenIBA 01/2017 - 03/2014
2	Silybin (Lagosa)IBA 05/2015 - 01/2012
2	Pharmaceutical PreparationsIBA 04/2015 - 04/2013
2	PlasticsIBA 02/2015 - 04/2013
2	Adrenergic Agents (Adrenergic Drugs)IBA 12/2013 - 01/2013
2	Phosphotransferases (Kinase)IBA 09/2011 - 06/2010
2	CytokinesIBA 06/2009 - 05/2007
2	Methionine (L-Methionine)FDA Link 03/2009 - 01/2006
2	DNA (Deoxyribonucleic Acid)IBA 03/2009 - 11/2002
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2009 - 03/2006
2	Glucose (Dextrose)FDA LinkGeneric 04/2006 - 09/2002
2	Apyrase (ATP Diphosphatase)IBA 04/2004 - 11/2002
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 05/2022
1	Acrolein (Aqualin)IBA 01/2022
1	SodiumIBA 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	Mesna (Coenzyme M)FDA LinkGeneric 01/2022
1	Superoxides (Superoxide)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	p38 Mitogen-Activated Protein KinasesIBA 01/2022
1	Uncoupling Protein 2IBA 01/2022
1	methyl isocyanateIBA 11/2020
1	Prolyl-Hydroxylase InhibitorsIBA 10/2020
1	Air Pollutants (Pollutants, Air)IBA 01/2020
1	Nitrogen DioxideIBA 01/2020
1	SootIBA 01/2020
1	Particulate MatterIBA 01/2020
1	PlacebosIBA 05/2019
1	Propranolol (Inderal)FDA LinkGeneric 01/2019
1	Phenobarbital (Luminal)FDA Link 01/2017

Therapy/Procedure

9	Therapeutics 10/2020 - 02/2004
2	Artificial Respiration (Mechanical Ventilation) 06/2007 - 02/2004
1	Critical Care (Surgical Intensive Care) 01/2022